251 related articles for article (PubMed ID: 24378104)
1. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
[TBL] [Abstract][Full Text] [Related]
2. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis.
Kang EJ; Lee SY; Kim HJ; Min KH; Hur GY; Shim JJ; Kang KH; Oh SC; Seo JH; Lee SY; Kim JS
Oncology; 2016; 90(2):103-11. PubMed ID: 26785048
[TBL] [Abstract][Full Text] [Related]
5. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
6. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
7. Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy.
Bostel T; Förster R; Schlampp I; Wolf R; Serras AF; Mayer A; Bruckner T; Welzel T; Schmidberger H; Debus J; Rief H
Tumori; 2016; 102(2):156-61. PubMed ID: 26166220
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China.
Yang Y; Ma Y; Sheng J; Huang Y; Zhao Y; Fang W; Hong S; Tian Y; Xue C; Zhang L
Chin J Cancer; 2016 Apr; 35():40. PubMed ID: 27112196
[TBL] [Abstract][Full Text] [Related]
9. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henk H; Teitelbaum A; Kaura S
Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Brown JE; Cook RJ; Lipton A; Costa L; Coleman RE
Breast Cancer Res Treat; 2010 Oct; 123(3):767-79. PubMed ID: 20574672
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
20. [Bone metastases in lung cancer].
Tsuya A; Fukuoka M
Clin Calcium; 2008 Apr; 18(4):455-9. PubMed ID: 18379026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
